Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders

PURPOSE: Epithelial ovarian cancer (EOC) is a molecularly diverse disease. Mitogen-activated protein kinase kinase (MEK) inhibition targets tumors harboring mitogen-activated protein kinase (MAPK) pathway alterations and enhances paclitaxel-induced apoptosis in EOC. This phase Ib study evaluated the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Grisham, Rachel N., Moore, Kathleen N., Gordon, Michael S., Harb, Wael, Cody, Gwendolyn, Halpenny, Darragh F., Makker, Vicky, Aghajanian, Carol A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6616528/
https://ncbi.nlm.nih.gov/pubmed/29844129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0494
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares